IGF-1 LR3
Long R3 IGF-I
IGF-1 LR3 is an insulin-like growth factor analogue with altered interactions with IGF-binding proteins. It is not native IGF-1, insulin or growth hormone.
Reviewed September 2026
- Residues
- 83. verified: 83 residues in the GSRS reference chain: mature 70-residue IGF-I domain plus a 13-residue N-terminal extension.
- Average mass
- 9,111.45 Da. calculated: Average neutral mass calculated from the GSRS 83-residue sequence with free termini, subtracting six H atoms for three disulfides; no salts/solvates. The registry’s separate estimated mass/formula are inconsistent with this explicit calculation and are not used.
- pI
- Not established. unverified: No full disulfide-aware pI model or documented value was established. A calculator treating the six disulfide cysteines as free thiols would not represent this reference structure.
Reference details
| Residues | 83 |
|---|---|
| Average mass | 9,111.45 Da |
| pI | Not established |
| Aliases | Long R3 IGF-I |
|---|---|
| Research area | Growth hormone |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Long-[Arg3]IGF-I reference: 83-residue chain with the documented 13-residue extension and three intramolecular disulfides. Mass is calculated from this specified sequence/oxidation state, not a measured product or an uncorrected registry estimate.
- Residues: 83 (verified). 83 residues in the GSRS reference chain: mature 70-residue IGF-I domain plus a 13-residue N-terminal extension. Residues source 1 Residues source 2
- Average mass: 9,111.45 Da (calculated). Average neutral mass calculated from the GSRS 83-residue sequence with free termini, subtracting six H atoms for three disulfides; no salts/solvates. The registry’s separate estimated mass/formula are inconsistent with this explicit calculation and are not used. Average mass source 1 Average mass source 2
- pI: Not established (unverified). No full disulfide-aware pI model or documented value was established. A calculator treating the six disulfide cysteines as free thiols would not represent this reference structure. pI source 1
Reference scope and linked records
Reference type: Modified protein analogue.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: IGF-1 LR3. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About IGF-1 LR3
Identity and context
The LR3 designation must remain attached to the identity. Sequence modifications and the folded, disulfide-containing structure matter for interpretation. A linear sequence alone does not establish the active conformation or biological potency of a protein preparation.
Reference classification
Modified protein analogue. The linked catalogue product is IGF-1 LR3. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Obtain the complete analogue identity, disulfide or folding assessment and an appropriate biological assay where the work requires activity. Analytical purity and receptor-related potency answer different questions.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | A primary study in growth-restricted fetal sheep reported that IGF-1 LR3 did not improve fetal growth in the tested setting, while circulating amino acids decreased. The authors discussed why nutrient availability and the experimental context might influence the result. | Source context |
| What cannot be inferred | This result illustrates why a growth-factor label is not a guarantee of growth in every model. It is not a human efficacy or safety trial, and it cannot establish the activity or potency of a catalogue lot. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheepPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.